The abstract is read at the publisher; the summary is JClub's.
ATRX protein loss is linked to significantly worse outcomes in uterine leiomyosarcoma (53%), undifferentiated pleomorphic sarcoma (37%), and dedifferentiated liposarcoma (8%).
- Why it matters: ATRX is frequently altered in sarcoma, but its clinical and therapeutic leverage has not been established, leaving a gap for biomarker-driven treatment options.
- What they did: In cohorts totaling n=127 STLMS, n=95 ULMS, n=82 UPS, and n=84 DDLPS, ATRX loss was tested for prognosis; mechanistically, ATRX knockout and PRDM4/NFIX knockdown were used alongside TEAD inhibitor VT103 and IAG933.
- The result: ATRX loss activated YAP1-TEAD signaling and made ATRX-deficient sarcoma cells and xenografts more sensitive to VT103 and IAG933, supporting TEAD inhibition as a potential strategy for ATRX-deficient tumors.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.